Find your next paid study

Theodore LaetschNCT06721689

Relapsed NeuroblastomaRefractory NeuroblastomaRelapsed Osteosarcoma+1 more

(INCITE-ON) Phase I Study of i15.NKG2D.Zeta-NK Cell Conditioning in the Tumor Micro-environment in Combination With C7R.GD2.CAR-T for the Treatment of Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

The purpose of this study is to find the largest safe dose of i15.NKG2D.zeta-NK cells in combination with C7R.GD2.CAR-T cells, and additionally to evaluate how…

Baylor College of MedicineNCT07211737

~$10 – $6,250

NeuroblastomaNeuroblastoma RecurrentRelapsed Neuroblastoma+1 more

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

This research is being done to investigate a treatment regimen of Irinotecan, Temozolomide, and Sargramostin, and an immunotherapy called Naxitamab and whether…

Steven DuBois, MDNCT07027748

Recurrent Solid TumorRecurrent Ewing SarcomaRecurrent Hepatoblastoma+19 more

A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma

The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back…

~$10 – $6,250

Relapsed NeuroblastomaRefractory NeuroblastomaHigh-risk Neuroblastoma

A Phase 1/2 Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

This Phase 1/2 trial aims to determine the safety and feasibility of administration of autologous chimeric antigen receptor (CAR) T cells targeting the human A…

Roberto ChiarleNCT06803875

Refractory NeuroblastomaRelapsed NeuroblastomaHigh-risk Neuroblastoma+2 more

Phase 1 Trial of GPC2-Directed Chimeric Antigen Receptor Autologous T Cells (GPC2 CAR T) for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

This is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblast…

Stephan Grupp MD PhDNCT05650749

NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma+2 more

A Phase I Study of Allogeneic Ex Vivo Expanded Gamma Delta (γδ) T Cells in Combination With Dinutuximab, Temozolomide, Irinotecan, and Zoledronate in Children With Refractory/ Relapsed, or Progressive Neuroblastoma or Refractory/ Relapsed Osteosarcoma

The goal of this clinical trial is to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of allogeneic expanded γδ T cells when de…